Roche has waved goodbye to an inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid for the therapy—as part of a ...
An updated report on cystic fibrosis (CF) from Ann & Robert H. Lurie Children's Hospital of Chicago, in partnership with the ...
Care for patients with cystic fibrosis has undergone transformative changes over the past decade and serves as an example of how an understanding of the functional consequences of a genetic disease ...
Angiotensin-converting enzyme (ACE) inhibitors were found to be independently associated with reducing all-cause mortality in ...
Large genetic study links telomere-related polygenic risk to distinct idiopathic pulmonary fibrosis subgroups, improving ...
Gene Expression Data Show Direct Impact on the Core Biology of IPF ...
Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. New research highlights the effectiveness of targeted therapies for ...
Presence of cardiac fibrosis puts high-level endurance athletes at increased risk for ventricular tachycardia while ...
Cystic fibrosis affects many parts of the body, but its effects on the lungs can be especially harmful. Cystic fibrosis is a chronic and progressive condition that causes the mucus in your lungs to be ...
In patients with cystic fibrosis, CMTX-101, an immune-enabling antibody therapy, lowered four inflammatory biomarkers and ...
Atypical cystic fibrosis is a mild form of cystic fibrosis. People with this type of cystic fibrosis can experience symptoms that come and go or that are less severe than those people with classic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results